Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Hematologic Neoplasms 3Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Lymphoma, Large-Cell, Anaplastic 2Sexual Dysfunction, Physiological 1Rare Tumor 1Neuroblastoma 1Lymphoma 1Lung Diseases 1Eunuchism 1Erectile Dysfunction 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Radiotherapy 3Nivolumab 3pembrolizumab 2Temozolomide 2Surveys and Questionnaires 2Paclitaxel 2ONC206 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Etoposide 2Cyclophosphamide 2Carboplatin 2Biopsy 2regorafenib 1pegfilgrastim 1mirdametinib 1lutetium Lu 177 dotatate 1fludarabine 1etoposide phosphate 1entrectinib 1entinostat 1elacestrant 1decitabine and cedazuridine drug combination 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1alectinib 1aflibercept 1abemaciclib 1Topotecan 1Tissue Banks 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Central Nervous System Neoplasms × alectinib × Clear all
NCT04774718 2026-05-05

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Hoffmann-La Roche

Phase 1/2 Recruiting
42 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡